News | April 19, 2025
GSK’s blenrep combinations approved by UK MHRA in relapsed/refractory multiple myeloma
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
The supply of these goods is set to commence within the first quarter of FY26
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
The portfolio includes branded injectable cephalosporines for infectious diseases
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
PRX-PLUS has a unique product feature with its deep-impacting formula
Subscribe To Our Newsletter & Stay Updated
